• Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab

  • Jul 18 2024
  • Length: 5 mins
  • Podcast

Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab

Listen for free

View show details

  • Summary

  • In this week’s podcast, Neurology Today’s editor-in-chief discusses data on an angiotensin receptor for blocker for hypertension associated with reduced risk for epilepsy, a study finding first responders to 9-11 clean-up sites had an increased risk for early dementia, and dementia experts comment on approval of donanemab.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Antihypertensive and reduced risk for epilepsy, first responders to 9-11 and early dementia risk, FDA approval of donanemab

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available